Advance of Research on the Immunotherapy Targeting B Cell Maration Antigen for Multiple Myeloma--Review.
10.19746/j.cnki.issn.1009-2137.2019.05.053
- Author:
Chun-Yan LUAN
1
;
Zi-Ying JIAN
1
;
Tao CHENG
2
;
Bao-An CHEN
3
Author Information
1. Department of Hematology Zhongda Hospital, Affiliated to Medical School of Southeast University, Nanjing 210009, Jiangsu Province, China.
2. Department of General Surgery, Zhongda Hospital, Affiliated to Medical School of Southeast University, Nanjing 210009, Jiangsu Province, China.
3. Department of Hematology Zhongda Hospital, Affiliated to Medical School of Southeast University, Nanjing 210009, Jiangsu Province, China.E-mail:cba8888@hotmail.com.
- Publication Type:Journal Article
- MeSH:
Antigens, Differentiation, B-Lymphocyte;
B-Cell Maturation Antigen;
B-Lymphocytes;
Humans;
Immunotherapy;
Multiple Myeloma;
therapy;
T-Lymphocytes
- From:
Journal of Experimental Hematology
2019;27(5):1701-1705
- CountryChina
- Language:Chinese
-
Abstract:
Abstract B cell maturation antigen (BCMA) is an ideal target for precise treatment due to its highly selective expression on malignant myeloma cells. This review summarizes briefly the advances in the latest research progress on biological activity of BCMA, its significance as a biomarker and immunotherapy direcited against BCMA, such as bispecific antibodies, antibody drug conjugates, chimeric antigen receptor T cell therapy against mature B cell antigens.
